Combination therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three treatments—a targeted artery procedure, a growth-blocking drug (apatinib), and an immune-boosting drug (camrelizumab)—for people with advanced liver cancer who cannot or do not want surgery. The goal is to shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 years
- Diagnosed with hepatocellular carcinoma (HCC, primary liver cancer) at stage B or C
- Measurable tumors visible on imaging (CT or MRI)
- Liver function rated as Child-Pugh grade A or well-controlled grade B (score ≤7)
- Good physical ability to tolerate treatment (ECOG score 0–1, meaning you can do most daily activities)
- Expected to live at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a combination of treatments—bland transarterial embolization (bTAE), hepatic artery infusion chemotherapy (HAIC), and systemic therapy—for people with large liver cancers that have limited spread. It might be an option if you have a big tumor and your liver is still working well.
This trial tests a combination of liver procedures (TACE or HAIC) with anti-angiogenic drugs and immunotherapy to shrink liver cancer that cannot be removed with surgery. If the tumor shrinks enough, you may be able to have surgery or continue with other treatments.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial tests a treatment given before surgery to shrink liver cancer and improve outcomes. It combines a liver-directed therapy (HAIC) with two oral drugs (lenvatinib and a PD-1 inhibitor) for people with intermediate-stage liver cancer that can be removed surgically.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.